Summary:
A phase 3 randomized. double-blind clinical trial to study the efficacy and safety of a fixed dose combination drug for the treatment of patients with type 2 diabetes and inadequate glycemic control on metformin mono therapy.
Qualified Participants Must:
• Be between 18 and 79 years of age
•
Be taking at least 1500mg of Metformin daily
•
Not be taking any lipid-lowering medications (high cholesterol meds)
•
Not have recently started a weight loss program or had bariatric surgery within last 12 months
Qualified Participants May Receive:
All study-related labs, doctor's exams, study medications free of charge and compensation may be available to qualified subjects.